Abstract
•Sarcopenia is associated with an increased risk of infections and mortality post-LT.•No data are available on the impact of sarcopenia in SLKT recipients.•Sarcopenia threshold was defined as TPA < 1460 mm2 (women) and <1560 mm2 (men).•Prospective and multi-centre studies are needed to evaluate frailty in this population.
The impact of sarcopenia in patients undergoing simultaneous liver and kidney transplantation (SLKT) has not been fully delineated. The aim of this single-centre-cohort-study was to evaluate the impact of sarcopenia on the clinical outcomes.
Between 2003 and 2018, 79 patients underwent SLKT. Sarcopenia was assessed via the total psoas muscle area (TPA) at the level of the 3rd. lumbar vertebra. Sarcopenia threshold was TPA < 1460 mm2 (women) and <1560 mm2 (men). We identified post-operative biliary, vascular and digestive complications. Survival analysis was performed by the Kaplan Meier method (log-rank test).
We included 43/79 SLKT recipients (56%male, median age of 58 [53−63] years). The prevalence of cirrhosis was 74% (n = 32) with median MELD-score of 21 (20−22) and that of polycystic-liver-disease was 26% (n = 11). End-stage-renal-disease of unknown origin was 36.2% (n = 12). Dialysis before transplantation was performed in 54,8% (n = 23) of patients. The median TPA was 1138 (926−1510) mm2, and sarcopenia was detected in 72% of patients (n = 31). No difference in patient or death-censored graft-survival between sarcopenic and non-sarcopenic groups at 1 year was reported. Also, no differences at 6-months’ post-transplant-complication-free and infection-free-survival rates were found.
In this cohort of patients, no differences were observed in patients, grafts, complications or infection-free survival between sarcopenic or no sarcopenic SLKT patients. Future multi-centre studies are needed to validate and extend the generalisability of these findings.